Operator
Ladies and gentlemen, welcome to the earnings call SCHOTT Pharma H1 2026. [Operator Instructions]
Let me now turn the floor over to your host, Tobias.
Tobias Erfurth
Head of Investor Relations
Thank you very much, Viara. Good morning, everyone, and welcome to SCHOTT Pharma’s earnings call for the first half of financial year 2026. My name is Tobias Erfurth, Head of Investor Relations, and I will guide you through today’s session. With me on the call are our CEO, Christian Mias; and our CFO, Reinhard Mayer.
As a reminder, and as announced in November 2025, Christian joined SCHOTT Pharma as new CEO on May 1. Christian, welcome once again. We are very happy to have you with us. And together with Reinhard, you bring extensive experience and fresh perspectives to SCHOTT Pharma. Christian will begin with a brief introduction and business update, followed by Reinhard, who will walk you through our financial performance in more detail. After that, we will open the call for your questions.
Before we begin, please take a moment to review our disclaimer. As a quick note, our financial year 2026 runs from October 1, 2025, to September 30, 2026. So the H1 results we are presenting today
